

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/16, 15/70, 1/21, C07K 14/575, A61K 38/22 // (C12N 1/21, C12R 1:19)</b>		<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 97/20933</b>
			<b>(43) International Publication Date:</b> 12 June 1997 (12.06.97)
<b>(21) International Application Number:</b> PCT/US96/18561 <b>(22) International Filing Date:</b> 3 December 1996 (03.12.96) <b>(30) Priority Data:</b> 08/568,077 6 December 1995 (06.12.95) US <b>(71) Applicant:</b> SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). <b>(72) Inventors:</b> ALTMANN, Scott, W.; 2821 Alma Street, Palo Alto, CA 94306 (US). ROCK, Fernando; 721 Shell Boulevard #203, Foster City, CA 94404 (US). BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US). <b>(74) Agents:</b> LUNN, Paul, G. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			<b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS			
<b>(57) Abstract</b>  Muteins, which are mutational variants of mammalian proteins. Particular positions of natural proteins are identified as critical in providing various different activities. Specific embodiments demonstrate properties of variations at these positions.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS

5

BACKGROUND OF THE INVENTION

Recent studies have identified a protein product, designated Ob, which  
when injected into a mouse causes that animal to lose weight. See, e.g., Barinaga  
(1995) Science 269:475-476; Zhang, et al. (1994) Nature 372:425-432;  
Pelleymounter, et al. (1995) Science 269:540-543; Halaas, et al. (1995) Science  
269:543-546; and Campfield, et al. (1995) Science 269:546-548. Mice deficient in  
active Ob gene product are grossly obese, but injection of the Ob protein causes  
the mice to curb their eating and shed fat.

Physiologically, it appears that the Ob protein has two activities, it  
decreases appetite and increases energy use, leading to metabolic deficit and loss  
of weight.

20

In the United States, up to one third of all Americans are overweight.  
Obesity is the cause of a myriad of serious health problems, including, e.g., sleep  
apnea, adult-onset diabetes, and heart disease. The availability of agonists and  
antagonists will be used to modulate these processes. The present invention  
provides these, as well as other proteins, useful, e.g., in determining the structure  
and mechanisms of weight and appetite regulation.

25

SUMMARY OF THE INVENTION

The present invention provides molecules which can serve as an agonist or  
antagonist for the Ob proteins. These agonists and antagonists will be useful in  
regulating weight and appetite regulation, and may be important in other  
hematopoietic or immunological function. In certain circumstances, these  
molecules will also have *in vitro* or *in vivo* therapeutic effects.

35

The present invention is based, in part, upon the recognition by structural  
analysis of the Ob sequence that it shares structural homology with a subclass of

proteins known as cytokines. Cytokines are proteins which mediate differentiation or other signals, typically between the circulating component of the mammalian circulatory system. Ob belongs to the subgroup of hematopoietic cytokines, which includes IL-2, IL-4, IL-5, GM-CSF, and growth hormone.

5

In particular, this insight leads to recognition of which specific amino acid residues of a cytokine-like protein are important in receptor binding. It embraces various mutein agonists and antagonists of natural ligands, e.g., specific mutations (muteins) of the natural sequences, fusion proteins, and chemical mimetics. It is also directed to DNAs encoding such variant proteins. Various uses of these different protein or nucleic acid compositions are also provided.

10

The present invention provides a mutein of a mammalian Ob which comprises a variation in sequence at a position in helix A; in helix C; in extruded loop from 100 to 108; or in helix D. In preferred embodiments, the position is in helix A; the mammalian Ob is mouse Ob, SEQ ID NO:1, rat Ob, SEQ ID NO: 2, or human Ob, SEQ ID NO: 3; the Ob has a sequence of SEQ ID NO: 1, 2, or 3; the variation is a non-conservative substitution; the substitution is at a position corresponding to D8, D9, K11, T12, K15, T16, V18, T19, I21, N22, N78, H78, D79, E81, N82, R84, D85, L86, V89, V123, V124, S127, R128, Q130, G131, S132, Q134, D135, or W138; the substitution is at a position corresponding to D8, D9, K11, T12, K15, T16, T19, E81, N82, R84, D85, R128, Q130, Q134, or D135; the substitution is selected from D8K, D9K, K11E, T12E, K15E, T16E, T19E, E81K, N82D, R84E, D85K, R128E, Q130K, Q134K, or D135K; and/or the variation is in the extruded loop at a position between 100 and 108, including deletion of WASGLETLD, SEQ ID NO: 6, of human Ob, deletion of QTSG LQKPE, SEQ ID NO: 7 of mouse Ob, or deletion of QTRGLQKPE, SEQ ID NO: 8, of rat Ob.

20

25

30

In other embodiments, the mutein exhibits at least about a 30% decrease in biological activity; exhibits less than about 80% maximal agonist activity; or exhibits at a 100-fold excess antagonist activity of said mammalian Ob by at least about 50%; will have a sequence variation which disrupts helical structure of helix A, C, or D; or will competitively compete with mammalian Ob.

35

The invention also embraces a pharmaceutical composition comprising the mutein a pharmaceutically acceptable carrier or excipient. It also embraces a nucleic acid encoding these muteins.

In other embodiments, the invention provides a method of antagonizing the biological activity of a mammalian Ob on a cell comprising contacting the cell with a described mutein. Preferably the method includes decreasing appetite or  
5 increasing metabolic rate in a mammal.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

### I. General

10

The present invention is based, in part, upon the recognition by structural analysis of the Ob sequence that it shares structural motifs and striking similarity to proteins known as hematopoietic cytokines. This is emphasized, e.g., by the similarity in the circular dichroism (CD) spectrum of Ob with other  
15 hematopoietic cytokines.

Many types of cells secrete cytokines, including red and white blood cells of the erythroid or the myeloid cell lineages. See, e.g., Rapaport (1987) Introduction to Hematology (2d ed.) Lippincott, Philadelphia, PA; Jandl (1987) Blood: Textbook of Hematology, Little, Brown and Co., Boston, MA.; and Paul (ed.)(1993) Fundamental Immunology (3d ed.), Raven Press, N.Y. Myeloid cell production occurs through the differentiation and later commitment of myeloid progenitor cell lineages.

25 In addition, functional interaction of the various cell types involved in immune responses often involve transfer of signals via soluble messenger molecules. Cytokines function through receptors, many of which have been characterized. See, e.g., Aggarwal and Gutterman (eds.) (1991) Human Cytokines: Handbook for Basic and Clinical Research, Blackwell, Oxford. The  
30 contact points between these ligands and their receptors have been established by experimental and modeling analysis to involve primarily the A and D helices with some contribution from the C helix.

It is presumed that the Ob protein operates through a similar biological  
35 signal mechanism, with the described effects on organismic physiology. Moreover, the similarity to cytokines may suggest additional effects on hematopoietic or immunological development or function.

The present invention provides sequence variants, also referred to as mutant proteins (muteins), of the Ob proteins, e.g., muteins, which serve as agonists and/or antagonists of the cytokines. The natural ligands are capable of mediating various biochemical responses which should lead to biological or physiological responses in target cells, e.g., as described above.

Table 1 shows the sequences of the mouse Ob protein, SEQ ID NO:1, the rat Ob protein, SEQ ID NO:2, and the human Ob protein, SEQ ID NO: 3.

Table 1: Mammalian Ob proteins sequences (mouse SEQ ID NO: 1, rat SEQ ID NO: 2, human SEQ ID NO: 3).

15	Mob	MCWRPLCRFLWLWSYLSYVQA	VPIQKVQDDT	KTLIKTIVTR	INDISHTQSV
	Rob	MCWRPLCRFLWLWSYLSYVQA	VPIHKVQDDT	KTLIKTIVTR	INDISHTQSV
	Hob	MHWGTLGFLWLWPYLFYVQA	VPIQKVQDDT	KTLIKTIVTR	INDISHTQSV
		* * * * *	* * * * *	* * * * *	* * * * *
20	Mob	SAKQRVGTGLD	FIPGLHPILS	LSKMDQTLAV	YQQVLTSLPS
	Rob	SARQRVGTGLD	FIPGLHPILS	LSKMDQTLAV	YQQILTSLPS
	Hob	SSKQKVTGLD	FIPGLHPILT	LSKMDQTLAV	YQQILTSMPs
		* * * * *	* * * * *	* * * * *	* * * * *
25	Mob	ENLRDLLHLL	AFSKSCSLPQ	TSGLQKPESL	DGVLEASLYS
	Rob	ENLRDLLHLL	AFSKSCSLPQ	TRGLQKPESL	DGVLEASLYS
	Hob	ENLRDLLHVL	AFSKSCHLPW	ASGLETLDL	GGVLEASGYS
		* * * * *	* * * * *	* * * * *	* * * * *
30	Mob	GSLQDILQQL	DVSPEC		
	Rob	GSLQDILQQL	DLSPEC		
	Hob	GSLQDMLWQL	DLSPGC		
		* * * * *	* * * * *		

The first 21 residues appear to be signal sequence, mature protein amino terminus begins at residue 22 (VPI...), residue numbering used herein is relative to that; \* denotes matching residues among all three sequences. Mouse Ob sequence is Genbank Accession Number U18812; rat is D45862; human is U128915.

With a selected cell line, a dose-response curve of the appropriate cytokine is performed. This gives a plateau, or maximal stimulation at saturating or excess amounts of cytokine. Typically, the cytokine will show a useful dose-response in the range of  $10^{-7}$  to  $10^{-13}$  M cytokine. The half maximal response typically will fall in the range of  $10^{-9}$  to  $10^{-12}$  M.

An Ob mutein candidate agonist is tested, preferably with a sequence substitution as described, by measuring biological activity upon administration. In one assay, a dose response curve of the Ob is titrated in the absence or presence of the candidate mutein at a fixed concentration. Typically the candidate mutein concentration is fixed, preferably within the range of equimolar to the half-maximum of the target cytokine, or at a 10-, 100-, or 1000- fold excess of candidate mutein over that half-maximum amount. Typically, the dose response curve of the cytokine will shift. The shift will normally be at least one log unit, often two to four log units.

10

To test partial agonist activity of the candidate mutein, a dose-response curve of the mutein is performed. Assays for biological activity in animals are known. Typically, the maximal stimulatory activity of the mutein will be near that of the natural cytokine, but partial agonists will show a suboptimal stimulation at saturation, e.g., the maximal activity will plateau at a lesser amount. Muteins are made typically by site specific mutagenesis of natural cytokine at defined positions.

The tertiary structural features of cytokines have been described, e.g., in Bazan (1991) Cell 66:9-10; Bazan (1990) Immunology Today 11:350-354; Bazan (1992) Science 257:410-413; Rozwarski, et al. (1994) Structure 2:159-173; and Sprang and Bazan (1993) Current Opinion in Structural Biology 3:815-827. These references define common structural features of the cytokines, e.g., the helices A, B, C, and D therein, including sequence alignments and corresponding positions. See also Zurawski, et al. (1993) EMBO J. 12:2663-2670; and the programs MATCH, SSPRED, ZIPPED, SSP, NNSSP, DSM, PHD, and MODELLER.

The specific positions of critical substitutions typically are conserved across different cytokines in various patterns, and because the helical turn involves 3.5 residues per turn, 3 or 4 residues and 7 residues in either direction will be positioned adjacent on the surface of a cytokine. Those residues which affect interaction between ligand and receptor will be primarily those located at the interaction point where the ligand substantially retains its native conformation. As such, the focus is on residues exposed to solvent, e.g., at the protein surface, and away from the residues which make up the core of the helix bundle. Residues internal to the secondary structure or tertiary conformation are thus avoided, as they often will cause a dramatic conformational disruption.

Helix A of the mammalian Ob corresponds to positions 4-24; helix B to positions 54-67; helix C to positions 75-92; and helix D to positions 117-142. The region of Ob protein predicted to interact with its receptor would be the A (and secondarily C) and D helices. Structurally, positions 10; 13, 14; 16, 17; and 20 in helix A; positions 80; 83; 86, 87; and 90, 91 in helix C; and positions 120; 122; 125, 126; 129; 132, 133; and 136 in helix D are each predicted to be in a helical structure whose surface is away from the receptor contact site and less critical in binding protein, e.g., receptor, interaction. Consequently, positions which would be on the helical surface contacting its receptor would be expected to have a more dramatic effect on interaction, e.g., binding or signalling.

Particularly important residues include, e.g., K11, T12, K15, T16, or T19 in helix A; R128, Q130, Q134, or D135 in helix D; E81, N82, R84, or D85 in helix C. Significant changes in the nature of the residue, e.g., charge reversal or significant size or hydrophobicity change, would be more likely to significantly affect physiological result. Also, significant disruption of the secondary structure, e.g., helical structure, would be also expected to abolish receptor interaction. Conservative substitutions generally would be expected to exhibit similar biological activity.

To maximize detectable effect, mutations are selected which would introduce significant changes in the residue, e.g., charge reversal, or change from hydrophobic to charged, or the opposite.

In addition, the Ob proteins exhibit an "extruded loop" structure, e.g., residues 100-108, which is not found in the related cytokines. Deletion of this segment results in a protein which lacks physiological activity, including appetite suppression and weight loss.

## II. Agonists; antagonists

The process of inhibition or prevention of agonist-induced responses is termed antagonism, and chemical entities with such properties are antagonists. See, e.g., Kenakin (1987) Pharmacological Analysis of Drug-Receptor Interaction Raven Press, NY.



Various classes of antagonists include chemical or neutralization antagonists, competitive antagonists, and noncompetitive antagonists. The chemical or neutralization antagonists typically interact with the agonist and prevent activation of the receptor and subsequent response, e.g., antibody antagonists which bind to the agonist and block signaling thereby.

Variant proteins are purified and subjected to physical analysis, e.g., CD spectral analysis, to determine whether the protein has a native-like conformation. Its binding behavior is tested, e.g., on cells expressing the protein's natural or recombinant receptor. The effects of the Ob variants may also be tested in the mice, e.g., the ob-/ob- animals.

The competitive antagonists typically are molecules which bind to the same recognition site on the receptor and block agonist binding. Noncompetitive antagonists bind to a site on the receptor distinct from the agonist binding site, and block signal transduction.

Measurement of antagonist activity and analysis of these results can be performed, e.g., by Schild analysis. See Arunlakshana and Schild (1959) Br. J. of Pharmacol. 14:48-58; and Chapter 9 of Kenakin (1987) Pharmacological Analysis of Drug-Receptor Interaction Raven Press, NY. See also Black (1989) Science 245:486-493. Schild analysis with a defined antagonist provides a number of means to evaluate quantity and quality of both agonist and receptor preparations. For example, analysis of a preparation of agonist allows better quality control indications than ELISA or mere bioassay quantitation methods. It provides means to distinguish between a denatured agonist, which is more likely to test positive in ELISA assays, and a biologically active agonist.

The described muteins are proteins, though a full length is not necessary. Fragments can be useful where they include positions which have been mutated as provided herein.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids.

Substantially pure typically means that the mutein is free from other contaminating proteins, nucleic acids, and other biologicals derived from the original source organism. Purity may be assayed by standard methods, typically by weight, and will ordinarily be at least about 80% pure, and in most preferred  
5   embodiments, at least about 95% pure.

The size and structure of the polypeptide should generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to  
10   confer solubility, or associated with lipids or detergents in a manner which approximates natural lipid bilayer interactions.

The solvent and electrolytes will usually be a biologically compatible buffer, of a type used for preservation of biological activities, and will usually  
15   approximate a physiological aqueous solvent. Usually the solvent will have a neutral pH, typically between about 5 and 10, and preferably about 7.5. On some occasions, one or more detergents will be added, typically a mild non-denaturing one, e.g., CHS or CHAPS, or a low enough concentration as to avoid significant  
20   disruption of structural or physiological properties of the ligand.

### III. Physical Variants

This invention also encompasses proteins or peptides having sequence variations at positions corresponding to the specified residues, but with substantial amino acid sequence identity at other segments. The variants include species variants and particularly molecules with the same primary sequence but variations beyond primary amino acid sequence, e.g., glycosylation or other modifications.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983) Chapter One in Time Warps, String Edits, and Macromolecules: The Theory and Practice of Sequence Comparison, Addison-Wesley, Reading, MA; and software packages from IntelliGenetics, Mountain View, CA; and the University of Wisconsin Genetics Computer Group, Madison, WI. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Members of a group do exhibit less dramatic structural differences, which may also be important.

Substitutions at designated positions can often be made with homologous residues to retain similar activities, e.g., agonist or antagonist functions. Identity measures will be at least about 85%, and usually at least about 95% or more, especially about the particular residue positions identified as appropriate for sequence changes. Regions of particular importance are within about 5 amino acids surrounding the defined positions, more particularly within about 8 amino acids, and preferably within about 11 amino acids adjacent the positions where changes are indicated.

The isolated cytokine DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of nucleotide stretches. These modifications result in novel DNA sequences which encode these proteins having many similar physiological, immunogenic, antigenic, or other functional activity. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms.

Cytokine mutagenesis can also be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy- terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See, e.g., Sambrook, et al. (1989); Ausubel, et al. (1987 and Supplements); and Kunkel, et al. (1987) Meth. Enzymol. 154:367-382.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from these proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. A similar concept applies to heterologous nucleic acid sequences.

In addition, new constructs may be made from combining similar functional domains from other proteins. For example, ligand-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992.

The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce suitable synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

"Derivatives" of these cytokines include amino acid sequence mutants at other positions remote from those specified, glycosylation variants, and covalent or aggregate conjugates with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in amino acid side chains or at the N- or C- termini, by standard means. See, e.g., Lundblad and Noyes (1988) Chemical Reagents for Protein Modification, vols. 1-

2, CRC Press, Inc., Boca Raton, FL; Hugli (ed.) (1989) Techniques in Protein Chemistry, Academic Press, San Diego, CA; and Wong (1991) Chemistry of Protein Conjugation and Cross Linking, CRC Press, Boca Raton, FL.

5           In particular, glycosylation alterations are included, e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. See, e.g., Elbein (1987) Ann. Rev. Biochem. 56:497-534. Also embraced are versions of the peptides with the same  
10       primary amino acid sequence which have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

          Fusion polypeptides between these Ob muteins and other homologous or heterologous proteins are also provided. Many growth factors and cytokines are  
15       homodimeric entities, and a repeat construct may have various advantages, including lessened susceptibility to proteolytic cleavage. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of a ligand, e.g., a receptor-binding segment, so that the presence or location of the fused ligand may be easily determined. See, e.g., Dull, et al., U.S. Patent No.  
20       4,859,609. Other gene fusion partners include bacterial  $\beta$ -galactosidase, trpE, Protein A,  $\beta$ -lactamase, alpha amylase, alcohol dehydrogenase, and yeast alpha mating factor. See, e.g., Godowski, et al. (1988) Science 241:812-816.

          Fusion peptides will typically be made by either recombinant nucleic acid  
25       methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, e.g., in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, Cold Spring Harbor Laboratory; and Ausubel, et al. (eds.) (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY. Techniques for synthesis of  
30       polypeptides are described, e.g., in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347; and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford; and Grant (1992) Synthetic Peptides: A User's Guide, W.H. Freeman, NY.

35           This invention also contemplates the use of derivatives of these Ob muteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical

moieties. Covalent or aggregative derivatives will be useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of receptors or other binding ligands. An Ob mutein can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated SEPHAROSE, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of anti-cytokine antibodies or its receptor. The Ob muteins can also be labeled with a detectable group, for use in diagnostic assays. Purification of Ob muteins may be effected by immobilized antibodies or receptor.

The present invention contemplates corresponding muteins the isolation of additional closely related species variants, e.g., rodents, lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

The invention also provides means to isolate a group of related muteins displaying both distinctness and similarities in structure, expression, and function. Elucidation of many of the physiological effects of the muteins will be greatly accelerated by the isolation and characterization of distinct species variants.

The isolated genes encoding muteins will allow transformation of cells lacking expression of a corresponding Ob protein, e.g., either species types or cells which exhibit negative background activity.

Dissection of critical structural elements which effect the various receptor mediated functions provided by cytokine binding is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390.

#### IV. Nucleic Acids

The described peptide sequences are readily made by expressing a DNA clone encoding the mutein, e.g., modified from a natural source, or a synthetic

gene. The synthetic gene may be based upon a preferred codon usage, e.g., for production in bacteria. A number of different approaches should be available to successfully produce a suitable nucleic acid clone.

- 5           The purified protein or defined peptides are useful as described above. Synthetic peptides or purified protein can be presented to an immune system to generate monoclonal or polyclonal antibodies which recognize specifically the muteins. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual,  
10       Cold Spring Harbor Press.

- This invention contemplates use of isolated DNA or fragments to encode a biologically active corresponding mutein. In addition, this invention covers isolated or recombinant DNA which encodes a biologically active antagonist or  
15       partial agonist protein or polypeptide.

- An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and  
20       flanking genomic sequences from the originating species. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule.  
25       Generally, the nucleic acid will be in a vector.

- An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a  
30       desired biological function or activity.

- A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g.,  
35       involving human intervention in the nucleotide sequence, typically selection or production. Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each

other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, for example, products made by transforming cells with any unnaturally occurring vector is encompassed, as are nucleic acids comprising sequence derived using any synthetic oligonucleotide process. Such is often done  
5 to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction  
10 enzyme recognition sites are often the target of such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, marker or purification tags, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically included are synthetic nucleic acids which,  
15 by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species variants.

Recombinant clones derived from genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and  
20 organisms, and for gene therapy. See, e.g., Goodnow (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology, Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (1987) (ed.) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, IRL Press,  
25 Oxford; and Rosenberg (1992) J. Clinical Oncology 10:180-199.

Substantial homology in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or  
30 deletions, in at least about 50% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence encoding a mutein.

## 35 V. Antibodies

Antibodies can be raised to portions of Ob proteins and which bind to the muteins described herein, including species or allelic variants, and fragments



thereof. Additionally, antibodies can be raised to Ob muteins in either their active forms or in their inactive forms. Anti-idiotypic antibodies are also contemplated.

5           Antibodies, including binding fragments and single chain versions, against predetermined fragments of the ligands can be raised by immunization of animals with conjugates of fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to fragments containing sequences  
10 including the specified modifications. These monoclonal antibodies will usually bind with at least a  $K_D$  of about 1 mM, preferably at least about 10  $\mu$ M, and more preferably at least about 3  $\mu$ M or better.

          The antibodies of this invention can also be useful in diagnostic  
15 applications. See e.g., Chan (ed.) (1987) Immunology: A Practical Guide, Academic Press, Orlando, FL; Price and Newman (eds.) (1991) Principles and Practice of Immunoassay, Stockton Press, N.Y.; and Ngo (ed.) (1988) Nonisotopic Immunoassay, Plenum Press, N.Y.

20           Mutein fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined polypeptides to be used as immunogens. A mutein or its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber Medical Division, Harper  
25 and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York; Williams, et al. (1967) Methods in Immunology and Immunochemistry, vol. 1, Academic Press, New York; and Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press, NY, for descriptions of methods of preparing polyclonal antisera.

30           In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange  
35 Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.), Academic Press, New

York; and particularly in Kohler and Milstein (1975) in Nature 256:495-497, which discusses one method of generating monoclonal antibodies. Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546.

The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; Moore, et al., U.S. Patent No. 4,642,334; and Queen, et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033.

The antibodies of this invention can also be used for affinity chromatography in isolating the Ob proteins. Columns can be prepared where the antibodies are linked to a solid support. See, e.g., Wilchek et al. (1984) Meth. Enzymol. 104:3-55.

Antibodies raised against each mutein will also be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

## VI. Making Agonists and Antagonists

DNA which encodes the Ob proteins or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or screening genomic libraries prepared from a wide variety of cell lines or tissue samples. See, e.g., Okayama and Berg (1982) Mol. Cell. Biol. 2:161-170; Gubler and Hoffman (1983) Gene

25:263-269; and Glover (ed.) (1984) DNA Cloning: A Practical Approach, IRL Press, Oxford. Suitable sequences can be obtained from GenBank.

5 This DNA can be mutated for expression in a wide variety of host cells for the synthesis of a full-length mutein or fragments which can in turn, e.g., be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for structure/function studies.

10 Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y.; Rodriguez, et al. (1988)(eds.) Vectors: A Survey of Molecular Cloning Vectors and Their Uses,  
15 Buttersworth, Boston, MA;

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a  
20 preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably linked means contiguous and in reading frame, however,  
25 certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression. See e.g., Rodriguez, et al., Chapter 10, pp. 205-236; Balbas and Bolivar (1990) Methods in Enzymology 185:14-37; and Ausubel, et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY.

30 Representative examples of suitable expression vectors include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610, see, e.g., Miller (1988) Ann. Rev. Microbiol. 42:177-199.

35 It will often be desired to express a mutein or polypeptide in a system which provides a specific or defined glycosylation pattern. See, e.g., Luckow and

Summers (1988) Bio/Technology 6:47-55; and Kaufman (1990) Meth. Enzymol. 185:487-511.

5 The appropriate mutein, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the antigen in a biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 10 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

Once a particular mutein has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid 15 Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; and Bodanszky (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York; and Villafranca (ed.) (1991) Techniques in Protein Chemistry II, Academic Press, San Diego, Ca.

20

## VII. Uses

The present invention provides reagents which will find use in therapeutic or diagnostic applications as described elsewhere herein, e.g., in the general 25 description for developmental abnormalities, or below in the description of kits for diagnosis.

The Ob protein muteins, fragments thereof, and antibodies thereto, should be useful in the evaluation or quality control of recombinant production of 30 natural Ob. They may also be useful *in vitro* or *in vivo* screening or treatment of conditions associated with abnormal physiology or development, including abnormal proliferation, e.g., cancerous conditions, or degenerative conditions. The structural relationship of the Ob protein to other cytokines suggests the possibility of biological activities beyond the food metabolic activities described. 35 In particular, modulation of cytokine activities should be useful in situations where the cytokine functions have been implicated, e.g., immunological responses, inflammation, autoimmunity, abnormal proliferation, regeneration,

degeneration, and atrophy of responsive cell types. For example, a disease or disorder associated with abnormal expression or abnormal signaling by Ob protein, besides the recognized effects, should be a potential target for treatment using an antagonist or agonist. The similarity in structures and mechanisms  
5 suggest potential hematopoietic or immunological functions may also exist.

Recombinant Ob protein muteins or, in some instances, antibodies can be purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active or inert ingredients, e.g., in conventional  
10 pharmaceutically acceptable carriers or diluents, e.g., appetite suppressors, along with physiologically innocuous stabilizers and excipients. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms  
15 which are not complement binding.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus,  
20 treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds.)  
25 (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others.

30 Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10  $\mu$ M concentrations,  
35 usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or a slow release apparatus will often be

utilized for continuous administration. See, e.g., Langer (1990) Science 249:1527-1533.

5 These Ob protein muteins may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical  
10 formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient.

15 Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 9th Ed., Pergamon Press; and  
20 Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Dekker, New York; and Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York. The  
25 therapy of this invention may be combined with or used in association with other agents.

30 The muteins of this invention are particularly useful in kits and assay methods which are capable of screening compounds for interactions with binding proteins. Two such binding proteins have sequences disclosed in SEQ ID NO: 4 and 5. These proteins each bind to Ob with specificity and high affinity. Several methods of automating assays have been developed in recent years so as  
35 to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of

binding affinity by a plurality of defined polymers synthesized on a solid substrate.

For example, antagonists can normally be found once the ligand has been structurally defined. Testing of potential ligand analogs is now possible, based upon an in vivo activity assay, or upon binding protein interaction. In particular, new agonists and antagonists will be discovered by using screening techniques described herein.

One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing the binding protein. Cells may be isolated which express a binding protein in isolation from any others. Such cells, either in viable or fixed form, can be used for standard ligand/receptor binding assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods to detect cellular responses.

Rational drug design may also be based upon structural studies of the molecular shapes of the agonists or antagonists and other effectors or analogs. Effectors may be other proteins which mediate other functions in response to ligand binding, or other proteins which normally interact with the receptor. One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

#### VIII. Kits

This invention also contemplates use of these muteins, proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for diagnosing the receptor interactions of an Ob protein. Typically the kit will have a compartment containing either a defined mutein peptide or a reagent which recognizes one, e.g., receptor fragments or antibodies.

A kit for determining the binding affinity of a test compound to a binding protein or receptor would typically comprise a test compound; a labeled compound, for example a receptor or antibody having known binding affinity for the cytokine or its mutein; a source of mutein; and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the mutein. Once compounds are screened, those having suitable binding affinity can be evaluated in suitable biological assays, as are well known in the art, to determine whether they act as agonists or antagonists.

Antibodies, including antigen binding fragments, specific for muteins or unique fragments are useful in diagnostic applications to detect the presence of the muteins. In certain circumstances, it will be useful to quantitate amounts of muteins in a sample. Diagnostic assays may be homogeneous (without a separation step between free reagent and antigen-ligand complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. See, e.g., Van Vunakis, et al. (1980) Meth Enzymol. 70:1-525; Harlow and Lane (1980) Antibodies: A Laboratory Manual, CSH Press, NY; and Coligan, et al. (eds.) (1993) Current Protocols in Immunology, Greene and Wiley, NY.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against a mutein, as such may be diagnostic of various abnormal states.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody or receptor, or labeled mutein is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.



Any of the aforementioned constituents of the drug screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In many of these assays, the test compound, mutein, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as  $^{125}\text{I}$ , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the bound from the free ligand, or alternatively the bound from the free test compound. The mutein can be immobilized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads. See, e.g., Coligan, et al. (eds.) (1993) Current Protocols in Immunology, Vol. 1, Chapter 2, Greene and Wiley, NY. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem. 30:1457-1461, and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678.

Methods for linking proteins or their fragments to the various labels have been extensively reported in the literature and do not require detailed discussion here. Many of the techniques involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the like. Fusion proteins will also find use in these applications.

Diagnostic kits which also test for the qualitative or quantitative presence of other markers are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g., Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97.

The broad scope of this invention is best understood with reference to the following examples, which are not intended to limit the invention to specific  
5 embodiments.

## EXAMPLES

### I. General Methods

5           Some of the standard methods are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols 1-3, CSH Press, NY; Ausubel, et al., Biology, Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and  
10 Supplements) Current Protocols in Molecular Biology, Greene and Wiley, New York; Innis, et al. (eds.)(1990) PCR Protocols: A Guide to Methods and Applications, Academic Press, N.Y.

          Methods for protein purification include such methods as ammonium  
15 sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification" in Methods in Enzymology vol. 182, and other volumes in this series; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway,  
20 N.J., or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, N.Y.; and Crowe, et al. (1992)  
25 OIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA. Cell culture techniques are described in Doyle, et al. (eds.) (1994) Cell and Tissue Culture: Laboratory Procedures, John Wiley and Sons, NY.

30           FACS analyses are described in Melamed, et al. (1990) Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY; Shapiro (1988) Practical Flow Cytometry Liss, New York, NY; and Robinson, et al. (1993) Handbook of Flow Cytometry Methods Wiley-Liss, New York, NY.

35

### II. Modifications to Ob protein sequence.

Methods for expression of a mutein Ob protein are as applied to a cytokine in *E. coli* described, e.g., in Zurawski, et al. (1986) J. Immunol. 137:3354-3360; and Zurawski and Zurawski, et al. (1988) EMBO J. 7:1061-1069. Cassette substitution mutagenesis is described in Zurawski and Zurawski (1989) EMBO J. 8:2583-2590.

5 For instance, a synthetic gene may be constructed by linking synthetic oligonucleotides, the gene sequence selected from preferred codon usage in, e.g., *E. coli*. In addition, a purification sequence, e.g., a FLAG signal may be added to assist in purification and/or detection. Refolding of recombinant protein may be performed using standard methods.

10

### III. Biological Assay of Sequence Variants.

Biological assay of Ob is described, e.g., in Pelleymounter, et al. (1995) Science 269:540-543; Halaas, et al. (1995) Science 269:543-546; and Campfield, et  
15 al. (1995) Science 269:546-548. Binding of the variants to the receptor may be assayed by standard binding assays, including surface plasmon resonance (BLAcore, Pharmacia) analysis. See Tartaglia, et al. (1995) Cell 83:1263 - 1271.

Alternatively, male ob/ob mice, aged 7 weeks, were individually housed  
20 in Nalgene metabolic cages in a reverse light (12 hours dark, 12 light) cycle room. Mice were given rodent chow pellets ad libitum. Mice were injected intraperitoneally (i.p.) with saline or 15 mg (in 0.18 ml; dilutions were done in sterile PBS) wild type or mutein, two times a day (b.i.d.) for three days. Injections occurred at onset of dark part of the cycle and 6 hours into the dark cycle. Food  
25 intake measurements were made at 2, 4, 6, and 24 hours post-first injection of each day. Body weight was measured each day prior to first injection of the day. Water intake, urine, and fecal output were also measured. Various means to measure metabolic rate are known in the art.

### 30 IV. Specific Variants.

One variant corresponding to human K11E; K15E exhibited about 50% activity of natural human Ob. A variant corresponding to a human Ob with deletion of the extruded loop exhibited virtually no biological activity. A variant  
35 corresponding to a human Ob Q130K; Q134K showed biological activity equivalent to natural Ob.

The following Ob variants have been made:

In the A helix: K11E/K15E.

- 5 In the D helix: R128E  
D135K  
R128E/D135K  
Q130K/Q134K.

10 These variations were selected primarily for the following reasons:

1. Ob is a member of the family of hematopoietic cytokines. There is much experimental data, e.g., from the interaction of growth hormone to its receptor, that the A and D helices are the primary ligand-receptor contact points, with a  
15 lesser effect from the C helix.
2. Residues in the A and D helices are selected that are exposed, and thus would contribute to receptor binding. Residues that make up the core of the helix bundle and are involved in general tertiary folding, are avoided. Note that  
20 certain of these residues point inside the helix and interact with one another to produce the helix, these are distinct from those which point outwards and would be solvent exposed.
3. For maximum effect, variations are selected that are as 'profound' as  
25 possible (e.g., when possible, charge reversal, R/K for E/D etc.).

These analyses have identified that there are at least two clearly exposed residues in the A-helix: K11 and K15. The double charge reversal variant shows an altered CD profile, suggesting that it is misfolded and which likely is the cause  
30 of the effects its biological activity.. Its biological activity is reduced.

These analyses have also identified four exposed residues in helix-D. The Q130/Q134 residues are located in a position predicted to cause only a minor effect on receptor binding (based on other cytokine/receptor interactions).  
35 Experimental evidence confirms this. The Q130/Q134 variant is biologically as active as wild type Ob.

The other two exposed residues, R128 and D135 are much more likely to be involved in ligand-receptor interaction. CD analysis shows relatively unaltered tertiary structures for R128E, D135K and the double mutant R128E/D135K. Biological analysis shows R128E/D135K to be inactive, D135K is almost inactive and, surprisingly, R128E is inactive and possibly even 'less' than inactive. Mice injected with R128E eat even less than mice injected with saline.

Binding studies show that all three mutant proteins can still bind with the same affinity to the leptin receptor. This suggests that these two residues are directly contacting a second receptor in a complex that consists, at a minimum, of Ob, the Ob receptor, and another unidentified receptor component. These proteins should behave as antagonists.

Other variants include a loop deletion. In this Ob model, there is an unstructured loop of 9 residues following the C-helix and going into the long C/D loop. This region is unique, as no other helical cytokine has an equivalent region. A variant has been constructed which has deleted this region and its biological activity and biophysical behavior have been tested.

There is a slight loss of alpha helicity, but the protein essentially is still biologically active. This is unexpected since this variant has a 9 amino acid deletion in the middle of the protein, but without affecting the protein fold. This provides strong evidence that the predicted fold for Ob and the positioning of this loop is correct.

#### V. Binding Protein Analysis.

Binding analyses of Ob variants to an Ob binding protein can be performed, see SEQ ID NO: 4 or 5. Receptor is made by standard recombinant methods, expressing a gene encoding said proteins. See Tartaglia, L., (1995) Cell 83:1263-1271. Assays will include a heterologous displacement format with labeled ligand at an appropriate concentration and various concentrations of purified Ob or mutant Ob proteins. Ob proteins and variants can be purified, or used in crude preparations. Data can be analyzed using the Ligand computer program, see Munson and Rodbard (1980) Anal. Biochem. 107:220-239. Binding protein interaction analyses can also performed on L cells expressing an Ob binding protein or receptor, derived by cotransfection by expression plasmids.

- Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only,
- 5 and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

(i) APPLICANT: Schering Corporation

(ii) TITLE OF INVENTION: MUTATIONAL VARIANTS OF MAMMALIAN  
PROTEINS

10

(iii) NUMBER OF SEQUENCES: 7

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: Schering-Plough Corporation

(B) STREET: 2000 Galloping Hill Road

(C) CITY: Kenilworth

(D) STATE: New Jersey

(E) COUNTRY: USA

(F) ZIP: 07033-0530

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: Apple Macintosh

(C) OPERATING SYSTEM: 7.5.3

25

(D) SOFTWARE: Microsoft Word 5.1a

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/568,077

(B) FILING DATE: 06-DEC-1995

30

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Lunn, Paul G.

(B) REGISTRATION NUMBER: 32,743

35

(C) REFERENCE/DOCKET NUMBER: DX0552 PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 908-298-5061

(B) TELEFAX: 908-298-5388

40

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

45

(A) LENGTH: 167 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single



(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

10	Met	His	Trp	Gly	Thr	Leu	Cys	Gly	Phe	Leu	Trp	Leu	Trp	Pro	Tyr	Leu	1	5	10	15
	Phe	Tyr	Val	Gln	Ala	Val	Pro	Ile	Gln	Lys	Val	Gln	Asp	Asp	Thr	Lys	20	25	30	
15	Thr	Leu	Ile	Lys	Thr	Ile	Val	Thr	Arg	Ile	Asn	Asp	Ile	Ser	His	Thr	35	40	45	
	Gln	Ser	Val	Ser	Ser	Lys	Gln	Lys	Val	Thr	Gly	Leu	Asp	Phe	Ile	Pro	50	55	60	
20	Gly	Leu	His	Pro	Ile	Leu	Thr	Leu	Ser	Lys	Met	Asp	Gln	Thr	Leu	Ala	65	70	75	80
	Val	Tyr	Gln	Gln	Ile	Leu	Thr	Ser	Met	Pro	Ser	Arg	Asn	Val	Ile	Gln	85	90	95	
25	Ile	Ser	Asn	Asp	Leu	Glu	Asn	Leu	Arg	Asp	Leu	Leu	His	Val	Leu	Ala	100	105	110	
30	Phe	Ser	Lys	Ser	Cys	His	Leu	Pro	Trp	Ala	Ser	Gly	Leu	Glu	Thr	Leu	115	120	125	
	Asp	Ser	Leu	Gly	Gly	Val	Leu	Glu	Ala	Ser	Gly	Tyr	Ser	Thr	Glu	Val	130	135	140	
35	Val	Ala	Leu	Ser	Arg	Leu	Gln	Gly	Ser	Leu	Gln	Asp	Met	Leu	Trp	Gln	145	150	155	160
40	Leu	Asp	Leu	Ser	Pro	Gly	Cys										165			

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

45 (A) LENGTH: 167 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Cys Trp Arg Pro Leu Cys Arg Phe Leu Trp Leu Trp Ser Tyr Leu  
 1 5 10 15  
 5 Ser Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys  
 20 25 30  
 Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr  
 35 40 45  
 10 Gln Ser Val Ser Ala Lys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro  
 50 55 60  
 Gly Leu His Pro Ile Leu Ser Leu Ser Lys Met Asp Gln Thr Leu Ala  
 65 70 75 80  
 Val Tyr Gln Gln Val Leu Thr Ser Leu Pro Ser Gln Asn Val Leu Gln  
 85 90 95  
 20 Ile Ala Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Leu Leu Ala  
 100 105 110  
 Phe Ser Lys Ser Cys Ser Leu Pro Gln Thr Ser Gly Leu Gln Lys Pro  
 115 120 125  
 25 Glu Ser Leu Asp Gly Val Leu Glu Ala Ser Leu Tyr Ser Thr Glu Val  
 130 135 140  
 Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Ile Leu Gln Gln  
 145 150 155 160  
 Leu Asp Val Ser Pro Glu Cys  
 165

35 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 167 amino acids  
 (B) TYPE: amino acid  
 40 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Cys Trp Arg Pro Leu Cys Arg Phe Leu Trp Leu Trp Ser Tyr Leu  
 1 5 10 15  
 50 Ser Tyr Val Gln Ala Val Pro Ile His Lys Val Gln Asp Asp Thr Lys  
 20 25 30  
 Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr  
 35 40 45  
 55 Gln Ser Val Ser Ala Arg Gln Arg Val Thr Gly Leu Asp Phe Ile Pro  
 50 55 60

	Gly	Leu	His	Pro	Ile	Leu	Ser	Leu	Ser	Lys	Met	Asp	Gln	Thr	Leu	Ala
	65					70					75					80
5	Val	Tyr	Gln	Gln	Ile	Leu	Thr	Ser	Leu	Pro	Ser	Gln	Asn	Val	Leu	Gln
					85					90					95	
	Ile	Ala	His	Asp	Leu	Glu	Asn	Leu	Arg	Asp	Leu	Leu	His	Leu	Leu	Ala
				100					105					110		
10	Phe	Ser	Lys	Ser	Cys	Ser	Leu	Pro	Gln	Thr	Arg	Gly	Leu	Gln	Lys	Pro
			115					120					125			
	Glu	Ser	Leu	Asp	Gly	Val	Leu	Glu	Ala	Ser	Leu	Tyr	Ser	Thr	Glu	Val
15		130					135					140				
	Val	Ala	Leu	Ser	Arg	Leu	Gln	Gly	Ser	Leu	Gln	Asp	Ile	Leu	Gln	Gln
	145					150					155					160
20	Leu	Asp	Leu	Ser	Pro	Glu	Cys									
					165											

## (2) INFORMATION FOR SEQ ID NO:4:

## 25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 440 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30

## (ii) MOLECULE TYPE: protein

## 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

	Met	Leu	Pro	Leu	Leu	Leu	Pro	Leu	Leu	Trp	Ala	Gly	Ala	Leu	Ala	Gln
	1				5					10					15	
40	Glu	Arg	Arg	Phe	Gln	Leu	Glu	Gly	Pro	Glu	Ser	Leu	Thr	Val	Gln	Glu
				20					25					30		
	Gly	Leu	Cys	Val	Leu	Val	Pro	Cys	Arg	Leu	Pro	Thr	Thr	Leu	Pro	Ala
			35					40					45			
45	Ser	Tyr	Tyr	Gly	Tyr	Gly	Tyr	Trp	Phe	Leu	Glu	Gly	Ala	Asp	Val	Pro
		50					55					60				
	Val	Ala	Thr	Asn	Asp	Pro	Asp	Glu	Glu	Val	Gln	Glu	Glu	Thr	Arg	Gly
50		65				70					75					80
	Arg	Phe	His	Leu	Leu	Trp	Asp	Pro	Arg	Arg	Lys	Asn	Cys	Ser	Leu	Ser
					85					90					95	
55	Ile	Arg	Asp	Ala	Arg	Arg	Arg	Asp	Asn	Ala	Ala	Tyr	Phe	Phe	Arg	Leu
				100					105					110		

	Lys	Ser	Lys	Trp	Met	Lys	Tyr	Gly	Tyr	Thr	Ser	Ser	Lys	Ile	Tyr	Val
			115					120					125			
5	Arg	Val	Met	Ala	Leu	Thr	His	Arg	Pro	Asn	Ile	Ser	Ile	Pro	Gly	Pro
		130					135					140				
	Gly	Val	Trp	Pro	Ser	Ser	Asn	Leu	Thr	Cys	Ser	Val	Pro	Trp	Val	Cys
10		145				150					155					160
	Glu	Gln	Gly	Thr	Pro	Pro	Ile	Phe	Ser	Trp	Met	Ser	Ala	Ala	Pro	His
					165					170					175	
15	Leu	Leu	Gly	Pro	Arg	Thr	Thr	Gln	Ser	Ser	Val	Leu	Thr	Ile	Thr	Pro
				180					185					190		
	Ala	Gln	Asp	His	Ser	Thr	Asn	Leu	Thr	Cys	Gln	Val	Thr	Phe	Pro	Gly
			195					200					205			
20	Ala	Gly	Val	Thr	Met	Glu	Arg	Thr	Ile	Gln	Leu	Asn	Val	Ser	Tyr	Ala
		210					215					220				
	Pro	Gln	Lys	Val	Ala	Ile	Ser	Ile	Phe	Gln	Gly	Asn	Ser	Ala	Ala	Phe
25		225				230					235					240
	Lys	Ile	Leu	Gln	Asn	Thr	Ser	Ser	Leu	Pro	Val	Leu	Glu	Gly	Gln	Ala
					245					250					255	
30	Leu	Arg	Leu	Leu	Cys	Asp	Ala	Asp	Gly	Asn	Pro	Pro	Ala	His	Leu	Ser
				260					265					270		
	Trp	Phe	Gln	Ala	Ser	Pro	Pro	Xaa	Asn	Ala	Thr	Pro	Ile	Ser	Asn	Thr
			275					280					285			
35	Gly	Val	Leu	Glu	Leu	Pro	Gln	Val	Gly	Ser	Ala	Glu	Glu	Gly	Asp	Phe
		290					295					300				
	Thr	Cys	Arg	Ala	Gln	His	Pro	Leu	Gly	Ser	Leu	Gln	Ile	Ser	Leu	Ser
40		305				310					315					320
	Leu	Phe	Val	His	Trp	Lys	Pro	Glu	Gly	Arg	Ala	Gly	Gly	Val	Leu	Gly
					325					330					335	
45	Ala	Val	Trp	Gly	Ala	Ser	Ile	Thr	Thr	Leu	Val	Phe	Leu	Cys	Val	Cys
				340					345					350		
	Phe	Ile	Phe	Arg	Val	Lys	Thr	Arg	Arg	Lys	Lys	Gln	Pro	Ser	Gln	Cys
			355					360					365			
50	Lys	Xaa	Thr	Asp	Asp	Val	Asn	Pro	Val	Met	Val	Ser	Gly	Ser	Arg	Gly
		370					375					380				
	His	Gln	His	Gln	Phe	Gln	Thr	Gly	Ile	Val	Ser	Asp	His	Pro	Ala	Glu
55		385				390					395					400
	Ala	Gly	Pro	Ile	Ser	Glu	Asp	Glu	Gln	Glu	Leu	His	Tyr	Ala	Val	Leu
					405					410					415	
60	His	Phe	His	Lys	Val	Gln	Pro	Gln	Glu	Pro	Lys	Val	Thr	Asp	Thr	Glu
				420					425					430		

Tyr Ser Glu Ile Lys Ile His Lys  
435 440

5 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 421 amino acids

(B) TYPE: amino acid

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

20	Met	Pro	Leu	Leu	Leu	Leu	Pro	Leu	Leu	Trp	Gly	Gly	Ser	Leu	Gln	Glu	1	5	10	15
	Lys	Pro	Val	Tyr	Glu	Leu	Gln	Val	Gln	Lys	Ser	Val	Thr	Val	Gln	Glu	20	25	30	
25	Gly	Leu	Cys	Val	Leu	Val	Pro	Cys	Ser	Phe	Ser	Tyr	Pro	Trp	Arg	Ser	35	40	45	
	Trp	Tyr	Ser	Ser	Pro	Pro	Leu	Tyr	Val	Tyr	Trp	Phe	Arg	Asp	Gly	Glu	50	55	60	
30	Ile	Pro	Tyr	Tyr	Ala	Glu	Val	Val	Ala	Thr	Asn	Asn	Pro	Asp	Arg	Arg	65	70	75	80
	Val	Lys	Pro	Glu	Thr	Gln	Gly	Arg	Phe	Arg	Leu	Leu	Gly	Asp	Val	Gln	85	90	95	
35	Lys	Lys	Asn	Cys	Ser	Leu	Ser	Ile	Gly	Asp	Ala	Arg	Met	Glu	Asp	Thr	100	105	110	
40	Gly	Ser	Tyr	Phe	Phe	Arg	Val	Glu	Arg	Gly	Arg	Asp	Val	Lys	Tyr	Ser	115	120	125	
	Tyr	Gln	Gln	Asn	Lys	Leu	Asn	Leu	Glu	Val	Thr	Ala	Leu	Ile	Glu	Lys	130	135	140	
45	Pro	Asp	Ile	His	Leu	Ser	Gly	Pro	Leu	Glu	Ser	Gly	Leu	Trp	Arg	Pro	145	150	155	160
	Thr	Arg	Leu	Ser	Cys	Ser	Leu	Pro	Gly	Ser	Cys	Val	Ala	Gly	Pro	Pro	165	170	175	
50	Leu	Thr	Phe	Ser	Trp	Thr	Gly	Asn	Ala	Xaa	Ser	Ala	Pro	Trp	Thr	Pro	180	185	190	
55	Arg	Pro	Xaa	Ala	Pro	Arg	Glu	Leu	Thr	Leu	Thr	Pro	Arg	Pro	Glu	Asp	195	200	205	

	His	Gly	Thr	Asn	Leu	Thr	Cys	Gln	Met	Lys	Arg	Gln	Gly	Ala	Gln	Val	
	210						215					220					
5	Thr	Thr	Glu	Xaa	Thr	Val	Gln	Leu	Asn	Val	Ser	Tyr	Ala	Pro	Gln	Thr	
	225					230					235					240	
	Ile	Thr	Ile	Phe	Arg	Asn	Gly	Ile	Ala	Leu	Glu	Ile	Leu	Gln	Asn	Thr	
10					245					250					255		
	Ser	Tyr	Leu	Pro	Val	Leu	Glu	Gly	Gln	Ala	Leu	Arg	Leu	Leu	Cys	Asp	
				260					265					270			
15	Ala	Pro	Ser	Asn	Pro	Pro	Ala	His	Leu	Ser	Trp	Phe	Gln	Gly	Ser	Pro	
			275					280					285				
	Ala	Leu	Asn	Ala	Thr	Pro	Ile	Ser	Asn	Thr	Gly	Ile	Leu	Glu	Leu	Arg	
	290						295					300					
20	Arg	Val	Arg	Ser	Ala	Glu	Glu	Gly	Gly	Phe	Thr	Cys	Arg	Ala	Gln	His	
	305					310					315					320	
	Pro	Leu	Gly	Phe	Leu	Gln	Ile	Phe	Leu	Asn	Leu	Ser	Val	Tyr	Ser	Leu	
25					325					330					335		
	Pro	Gln	Leu	Leu	Gly	Pro	Ser	Cys	Ser	Trp	Glu	Ala	Glu	Gly	Leu	His	
				340					345					350			
30	Cys	Arg	Cys	Ser	Phe	Arg	Ala	Arg	Pro	Ala	Pro	Ser	Leu	Cys	Trp	Arg	
			355					360					365				
	Leu	Asp	Glu	Lys	Pro	Leu	Glu	Gly	Asn	Ser	Ser	Gln	Gly	Ser	Phe	Lys	
	370						375					380					
35	Val	Asn	Ser	Ser	Ser	Ala	Xaa	Pro	Gly	Gln	Gln	Leu	Pro	Asp	Pro	Pro	
	385					390					395					400	
	Arg	Gly	Ala	Gln	Leu	Arg	Thr	Ser	Lys	Ser	Ala	Ala	Arg	Pro	Gly	Thr	
40					405					410					415		
	Ser	Met	Gly	Pro	Glu												
					420												

## (2) INFORMATION FOR SEQ ID NO:6:

45

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

50

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: polypeptide

55

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Trp Ala Ser Gly Leu Glu Thr Leu Asp  
 1 5

5

## (2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 9 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: polypeptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Gln Thr Ser Gly Leu Gln Lys Pro Glu  
 1 5

## (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 9 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: polypeptide

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gln Thr Arg Gly Leu Gln Lys Pro Glu  
 1 5

45

## WHAT IS CLAIMED IS:

1. A mutein of a mammalian Ob which comprises a variation in sequence at a position:
  - 5 a) in helix A;
  - b) in helix C;
  - c) in extruded loop from 100 to 108; or
  - d) in helix D.
- 10 2. The mutein of Claim 1, wherein said position is in helix A.
3. The mutein of Claim 1, wherein said mammalian Ob is mouse Ob, rat Ob, or human Ob.
- 15 4. The mutein of Claim 1, wherein said Ob has a sequence of SEQ ID NO: 2, 4, or 6.
5. The mutein of Claim 1, wherein said substitution is at a position corresponding to D8, D9, K11, T12, K15, T16, V18, T19, I21, N22, N78, H78, D79,  
20 E81, N82, R84, D85, L86, V89, V123, V124, S127, R128, Q130, G131, S132, Q134, D135, or W138.
6. The mutein of Claim 5, wherein said substitution is at a position corresponding to D8, D9, K11, T12, K15, T16, T19, E81, N82, R84, D85, R128,  
25 Q130, Q134, or D135.
7. The mutein of Claim 6, wherein said substitution is selected from D8K, D9K, K11E, T12E, K15E, T16E, T19E, E81K, N82D, R84E, D85K, R128E, Q130K, Q134K, or D135K.  
30
8. The mutein of Claim 1, which comprises a variation in said extruded loop at a position between 100 and 108.
9. The mutein of Claim 8, wherein said variation is:  
35 a) deletion of WASGLETLD (SEQ ID NO: 6) of human Ob;  
b) deletion of QTSGLQKPE (SEQ ID NO: 7) of mouse Ob; or  
c) deletion of QTRGLQKPE (SEQ ID NO: 8) of rat Ob.



10. A pharmaceutical composition comprising:
- 5        1) a mutein of Claim 1, and
- 2) a pharmaceutically acceptable carrier or excipient.
11. A nucleic acid encoding a mutein of Claim 1.
- 10    12. A vector containing the nucleic acid of claim 12.
13. A cell transfected or transformed with the nucleic acid of claim 11 or vector of claim 12.
- 15    14. A method of decreasing appetite or increasing metabolic rate in a mammal, said method comprising administering to said mammal an effective amount of a mutein of Claim 1.
15. A method for the manufacture of a pharmaceutical composition for
- 20    treating obesity comprising admixing a mutein of claim 1 with a pharmaceutically acceptable carrier.
16. The use of a mutein of claims 1-9 for the treating of obesity.
- 25    17. The use of a mutein of claims 1-9 for the manufacture of a medicament for treating obesity.

**THIS PAGE BLANK (USPTO)**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C12N 15/16, 15/70, 1/21, C07K 14/575, A61K 38/22 // (C12N 1/21, C12R 1:19)</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 97/20933</b> <b>(43) International Publication Date:</b> 12 June 1997 (12.06.97)
<b>(21) International Application Number:</b> PCT/US96/18561 <b>(22) International Filing Date:</b> 3 December 1996 (03.12.96) <b>(30) Priority Data:</b> 08/568,077                      6 December 1995 (06.12.95)                      US <b>(71) Applicant:</b> SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). <b>(72) Inventors:</b> ALTMANN, Scott, W.; 2821 Alma Street, Palo Alto, CA 94306 (US). ROCK, Fernando; 721 Shell Boulevard #203, Foster City, CA 94404 (US). BAZAN, J., Fernando; 775 University Drive, Menlo Park, CA 94025 (US). KASTELEIN, Robert, A.; 463 Summit Drive, Redwood City, CA 94062 (US). <b>(74) Agents:</b> LUNN, Paul, G. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 2 October 1997 (02.10.97)
<b>(54) Title:</b> MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS  <b>(57) Abstract</b>  Muteins, which are mutational variants of mammalian proteins. Particular positions of natural proteins are identified as critical in providing various different activities. Specific embodiments demonstrate properties of variations at these positions.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 96/18561

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/16 C12N15/70 C12N1/21 C07K14/575 A61K38/22  
/(C12N1/21,C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NATURE, vol. 372, no. 6505, 1 December 1994, pages 425-432, XP000602062 YIYING ZHANG ET AL: "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE" see page 431, left-hand column, paragraph 2 - right-hand column, last paragraph; figure 6 ---	1,14,16, 17
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 209, no. 3, 26 April 1995, pages 944-952, XP000602094 TAKASHI MURAKAMI ET AL: "CLONING OF RAT OBESE CDNA AND ITS EXPRESSION IN OBESE RATS" see figure 2 --- -/--	1,14,16, 17

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

7 August 1997

Date of mailing of the international search report

18.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Fuhr, C

# INTERNATIONAL SEARCH REPORT

Patent Application No  
PCT/US 96/18561

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 96 05309 A (UNIV ROCKEFELLER ;FRIEDMAN JEFFREY M (US); ZHANG YIYING (US); PROE) 22 February 1996 see claims; examples ---	1,10-17
P,X	EP 0 725 078 A (LILLY CO ELI) 7 August 1996 see claims; examples ---	1-6, 10-17
P,X	EP 0 725 079 A (LILLY CO ELI) 7 August 1996 see claims; examples ---	1-6, 10-17
P,X	WO 96 24670 A (LILLY CO ELI ;BASINSKI MARGRET B (US); SCHONER BRIGITTE E (US)) 15 August 1996 see page 5, line 10 - line 40; claims; examples ---	1-4, 10-17
P,X	EP 0 744 408 A (LILLY CO ELI) 27 November 1996 see claims; examples ---	1-6, 10-17
P,X	EP 0 743 321 A (LILLY CO ELI) 20 November 1996 see claims; examples -----	1-6, 10-17

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/18561

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14, 16  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 14 and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/18561

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9605309 A	22-02-96	AU 3329895 A	07-03-96
		CA 2195955 A	22-02-96
		DE 19531931 A	07-03-96
		EP 0777732 A	11-06-97
		FI 970656 A	17-02-97
		GB 2292382 A,B	21-02-96
		JP 9502729 T	18-03-97
		NO 970683 A	16-04-97
		PL 319021 A	21-07-97
		ZA 9506868 A	09-04-96
EP 0725078 A	07-08-96	AU 4705296 A	21-08-96
		AU 4766196 A	21-08-96
		EP 0725079 A	07-08-96
		WO 9623515 A	08-08-96
		WO 9623517 A	08-08-96
EP 0725079 A	07-08-96	AU 4705296 A	21-08-96
		AU 4766196 A	21-08-96
		EP 0725078 A	07-08-96
		WO 9623515 A	08-08-96
		WO 9623517 A	08-08-96
WO 9624670 A	15-08-96	AU 4862396 A	27-08-96
EP 0744408 A	27-11-96	AU 5800696 A	11-12-96
		WO 9637517 A	28-11-96
EP 0743321 A	20-11-96	AU 5795496 A	29-11-96
		WO 9636644 A	21-11-96